Table 3. Number of patients tested and proportions of multidrug-resistant Enterobacteriaceae (MDRE) in screening and clinical cultures, during 2014–2015, at the Certe laboratory.
| Number of patients | % MDRE | % ESBL | % QARE | % CPE | |
|---|---|---|---|---|---|
| MDRE screening | |||||
| General patient population* | 1763 | 24.4% | 16.3% | 12.5% | 0.06% |
| Asylum seekers | 751 | 21.0% | 20.0% | 4.4% | 0.1% |
| Relative Risk (95% CI) | 0.9 (0.7–1.0) | 1.2 (1.0–1.5) | 0.4 (0.2–0.5) | 2.4 (0.1–85.6) | |
| Enterobacteriaceae in clinical samples | |||||
| General patient population | 31,798 | 4.6% | 2.7% | 2.6% | 0.02% |
| Asylum seekers | 150 | 21.3% | 19.3% | 7.3% | 0.0% |
| Relative Risk (95% CI) | 4.6 (3.3–6.3) | 7.2 (5.0–10.0) | 2.8 (1.5–5.1) | 0.0 (0–196.5) | |
| totals from screening and clinical samples** | |||||
| General patient population | 32,616 | 5.1% | 3.2% | 2.8% | 0.02% |
| Asylum seekers | 859 | 21.4% | 20.3% | 4.9% | 0.1% |
| Relative Risk (95% CI) | 4.2 (3.7–4.8) | 6.3 (5.5–7.3) | 1.75 (1.3–2.4) | 6.33 (0.3–52.4)) | |
* screened at hospital admission because of increased risk of MDRE carriage
** 945 of the general patient population and 42 asylum seekers had both screening and clinical cultures (number of totals less than sum of screening and clinical samples)